The human ribosomes are the cellular machines that participate in protein synthesis, which is deeply affected during cancer transformation by different oncoproteins and is shown to provide cancer cell proliferation and therefore biomass. Cancer diseases are associated with an increase in ribosome biogenesis and mutation of ribosomal proteins. The ribosome represents an attractive anti-cancer therapy target and several strategies are used to identify specific drugs. Here we review the role of different drugs that may decrease ribosome biogenesis and cancer cell proliferation.

Ribosome-directed therapies in cancer / Temaj, Gazmend; Chichiarelli, Silvia; Eufemi, Margherita; Altieri, Fabio; Hadziselimovic, Rifat; Farooqi, Ammad Ahmad; Yaylim, Ilhan; Saso, Luciano. - In: BIOMEDICINES. - ISSN 2227-9059. - 10:9(2022), p. 2088. [10.3390/biomedicines10092088]

Ribosome-directed therapies in cancer

Chichiarelli, Silvia
;
Eufemi, Margherita;Altieri, Fabio;Saso, Luciano
2022

Abstract

The human ribosomes are the cellular machines that participate in protein synthesis, which is deeply affected during cancer transformation by different oncoproteins and is shown to provide cancer cell proliferation and therefore biomass. Cancer diseases are associated with an increase in ribosome biogenesis and mutation of ribosomal proteins. The ribosome represents an attractive anti-cancer therapy target and several strategies are used to identify specific drugs. Here we review the role of different drugs that may decrease ribosome biogenesis and cancer cell proliferation.
2022
ribosome; cancer; target drugs; rRNA and tRNA inhibition
01 Pubblicazione su rivista::01g Articolo di rassegna (Review)
Ribosome-directed therapies in cancer / Temaj, Gazmend; Chichiarelli, Silvia; Eufemi, Margherita; Altieri, Fabio; Hadziselimovic, Rifat; Farooqi, Ammad Ahmad; Yaylim, Ilhan; Saso, Luciano. - In: BIOMEDICINES. - ISSN 2227-9059. - 10:9(2022), p. 2088. [10.3390/biomedicines10092088]
File allegati a questo prodotto
File Dimensione Formato  
Temaj_Ribosome_2022.pdf.pdf

accesso aperto

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Creative commons
Dimensione 1.31 MB
Formato Adobe PDF
1.31 MB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1654066
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 11
  • ???jsp.display-item.citation.isi??? 9
social impact